Sanofi stock rises as Dupixent shows benefit in lung disease smokers, meets phase 3 goals

Sanofi Distribution Centre in Kirkland, Quebec, Canada.


Sanofi (NASDAQ:SNY) and Regeneron Pharmaceuticals’ (NASDAQ:REGN) Dupixent met the main goal and all key secondary goals of a phase 3 trial to treat adults who were current or former smokers with chronic obstructive pulmonary disease (COPD).

The French pharma giant

Source link